Beone Medicines

This study tests whether a new drug combination (zanubrutinib plus rituximab) works better than standard chemotherapy (bendamustine plus rituximab) for people with mantle cell lymphoma who have not had treatment before and cannot have a stem cell transplant. About 510 adults aged…

This study tests a new drug (sonrotoclax) alone or with another drug (zanubrutinib) in people with Waldenström macroglobulinemia, a rare blood cancer. The goal is to see if the treatment shrinks tumors and controls the disease. About 114 adults with either newly diagnosed or retu…

This early-phase study tests a new drug called BGB-C354, which delivers a cancer-killing agent directly to tumor cells. It is given alone or with another drug (tislelizumab) that helps the immune system attack cancer. The study includes about 120 adults with advanced solid tumors…

This study tests an experimental drug called BGB-11417 (sonrotoclax) in people with certain B-cell blood cancers that have come back or not responded to prior treatment. The main goals are to find the safest dose and to check for side effects when given alone or combined with oth…

This study tests a new drug called BGB-21447 for people with certain blood cancers (like lymphoma and leukemia) that have returned or not improved after prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors. About 112 participants will re…

This phase 2 study tests whether adding sonrotoclax to the standard drug zanubrutinib works better than zanubrutinib alone for adults with untreated chronic lymphocytic leukemia (CLL). About 94 participants will receive either the combination or the single drug. The goal is to se…

This study tests a drug called zanubrutinib in people with primary membranous nephropathy, a kidney disease that causes protein to leak into urine. The goal is to see if zanubrutinib can reduce protein levels and lead to remission better than the current standard drug, tacrolimus…

This phase 3 study tests whether a new drug pair (sonrotoclax plus zanubrutinib) works better than the current standard (venetoclax plus obinutuzumab) for people with untreated chronic lymphocytic leukemia (CLL). About 652 adults with CLL who need treatment will be randomly assig…

This study looks at the long-term safety and effects of certain cancer drugs in people with advanced tumors. Participants must have already been in a related earlier study and still benefit from the treatment. The goal is to track side effects and see how well the drugs work over…